One of the unique glands in the human body is the pituitary gland. The gland is oval and weighs 500 mg. The dimension of the pituitary gland is about 12 mm transverse and 8 mm in anterior-posterior diameter. The pituitary is located in the hypophysial fossa, in a bony depression of the sphenoid bone called the sella turcica. The sella turcica surrounds the inferior, anterior, and posterior aspects of the gland. Various structures surround the endocrine gland. The optic chiasma lies anteriorly, and the mammillary bodies lie posteriorly. Superior to the pituitary gland is the diaphragma sellae, inferior lies the sphenoidal air sinuses, and lateral is the cavernous sinuses. A fold of dura matter covers the pituitary and has an opening to allow for the infundibulum to pass through, allowing a connection to the hypothalamus.
The gland consists of two lobes:
This article focuses on the adenohypophysis. The anterior pituitary is composed of the following parts:
These hormones are secreted in response to the prohormones that are secreted by the hypothalamus.
The adenohypophysis is characterized by well-demarcated acini. These acini are composed of a mixture of different hormone-producing cells. The different cells can be differentiated via hemotoxin and eosin (H and E) stains and the PAS-OG preparations. There are three distinct cell types seen based on these stains.
Adrenocorticotropic hormone (ACTH)
ACTH hormone is secreted in response from corticotropin-releasing hormone (CRH) from the hypothalamus gland. The CRH would travel from the hypothalamus to its portal system. Upon reaching the adenohypophysis, it stimulates the cleavage of the proopiomelanocortin (POMC) into several molecules. The three major ones are ACTH, melanocyte-stimulating hormone (MSH), and beta-endorphins. ACTH would travel via the bloodstream to stimulate the adrenal cortex to help stimulate the production of cortisol. Cortisol also exerts negative feedback to inhibit the release of CRH and ACTH.
The control of prolactin is primarily under the control of the hypothalamus. Dopamine is the predominant hormone in inhibiting the secretion of prolactin. When the hypothalamus receives afferent sensory nerve cell input from the nipple stimulation of lactating women, it will cause the feedback loop of inhibition of prolactin to reverse. Due to the suckling, there would be inhibition of dopamine release. This would allow an unopposed release of prolactin. Prolactin helps with the growth and development of the breasts and the maintenance of lactation in women.
These two hormones are produced by the gonadotrophin cells in the adenohypophysis.
In women: LH acts on the ovaries to stimulate steroid hormone production. FSH stimulates the follicular development of the ovary in women, more specifically the granulosa cells.
In men: LH acts by stimulating the Leydig cells in the testes to secrete testosterone. FSH stimulates the Sertoli cells to secrete androgen-binding proteins to initiate spermatogenesis.
In both males and females, these hormones help stimulate the maturation of primordial germ cells.
The control of LH and FSH is under the control of gonadotropin-releasing hormone (GnRH) produced by the hypothalamus. There is a negative feedback loop for LH and FSH from steroid sex hormones. Inhibin allows for more specific feedback for FSH.
Growth Hormone (GH)/Somatotropin
The growth hormone exerts its effects on many tissues. Growth hormone promotes linear growth via:
GH stimulates the many tissues and the liver to produce somatomedins. Somatomedin helps stimulates cell division and cell proliferation. Somatomedins have the following effects:
Growth hormone-releasing hormone (GHRH) is released by the hypothalamus, on which it reacts with the cells in the anterior pituitary. There is negative feedback on GH from the increase in the circulating concentrations of GH and IGF-1.
Thyroid-Stimulating Hormone (TSH)
The purpose of TSH is to stimulate the thyroid gland to help in the production and the release of T3 and T4.
Thyrotropin-releasing hormone (TRH) is released via the hypothalamus to the adenohypophysis. The TRH stimulates thyrotrophic cells to secrete TSH.
The pituitary gland is a unique gland due to its dual origin. The organogenesis of the pituitary begins in the fourth week in the development of the fetus. It starts with the formation of a structure called hypophyseal placode. This is formed when there is a thickening of the cells of the oral portion of the ectoderm. The hypophyseal placode brings forth Rathke’s pouch. The pouch extends upward in the direction of the neural ectoderm. It is simultaneously that there is a ventral portion of the diencephalon that gives a downward to expansion to form the neurohypophysis. Around 6 to 8 weeks Rathke’s pouch would constrict at the base, allowing it to separate from the portion of oral epithelium. The cells in the pouch start to undergo proliferation. The anterior portion of the wall of the pouch undergoes rapid proliferation to give rise to the anterior part of the lobe of the pituitary (pars distalis). The posterior portion of the wall would proceed at a slower rate and gives rise to the intermediate lobe (pars intermedia). There is an upward outward growth of the anterior wall that would form the pars tuberalis.
The pituitary gland development can be a complex embryological process. Transcriptions factors control this process.
Pituitary Organogenesis Initiation Along with the Formation of Rathke’s Pouch
These are homeodomain proteins that are a group of six transcriptional factor activators and inhibitors. The expression of these proteins persists even in adulthood.
This homeobox gene expression begins in the cells that become Rathke’s pouch. This is important in the development of the optic nerves. Clinically loss of function of this gene leads to solitary growth hormone deficiency, underdevelopment of the optic nerve, an absence of the septum pellucidum, and pituitary gland dysfunction giving pituitary hormone deficiency.
This transcription factor helps regulate Hesx1. Mutations in this factor also present as ocular disorders that might or might not give hypopituitarism.
Pitx forms 1, 2, and 3
Help decide cell lineage and mutations are found in those showing Axenfeld-Rieger syndrome. LH-beta and FSH-beta are not expressed.
The Is11 is a transcription factor that is involved in the specification of the lineage of the cells seen in the thyrotrophs.
LHX3 and LHX4
LHX3 seen in the early development of Rathke’s pouch. In the absence of the LHX3, there would not be thickening of the Rathke’s pouch, hearing loss that is sensorineural and, a short, stiff neck. When there is a lack of LHX4, there is a marked reduction in the numbers of lactotrophs and somatotroph cells, pituitary hypoplasia, Chiari malformation, and small sella.
The factor is expressed in the developing Rathke’s pouch. A mutation in this factor is seen in those with microphthalmia, deficiency of the growth hormone, and hypogonadotropic hypogonadism. Hypopituitarism would occur due to mutations that cause loss of function.
This factor would help activate Pitx2 expression. It is also required for cell lineage fate via Pit1 and the adenohypophysis formation.
It helps determine the fate of cell lineage and lateral inhibition is mediated.
Migration of Rathke’s Pouch Along with the Proliferation of the Cells
Induces Is11 expression but the prolonged-expression of this factor would result in a hyperplastic pituitary.
Required for the formation of the hypophyseal placode; the downregulation of this bone morphogenic protein would result in the arrested development of Rathke’s pouch.
This factor would be expressed in the oral portion of the ectoderm and ventral part of the diencephalon.
Determination of Cellular Lineage and Differentiation of Cellular Components
This transcription factor is observed on the 14th day of fetal development and would continue throughout life. Dimers are formed with other transcription factors such as Zn-15, HESX-I, P-Lim, thyroid hormone, estrogen, and retinoic acid receptor. Loss of this transcription factor would cause the loss of thyrotrophs, somatotrophs, and lactotrophs.
SF1 regulates the expression of GnRH, LH, and FSH and alphaGSU. The expression of this transcription factor is necessary for the differentiation of the gonadotrophs. Mutations gonadal dysgenesis in males while females would present with early ovarian failure.
GATA2 specifies gonadotroph and thyrotroph lineages.
The product of this gene is required for the expression. Loss of the expression of this gene leads to deficiencies in GH, prolactin, TSH, LH, and FSH.
The expression is normally seen in the brain and the posterior pituitary gland. In experimental mice, the disruption of this gene leads to pituitary gland aplasia.
Out of all these transcription factors, it is the mutation of Pit-I and PROP-I that leads to familial cases of multiple pituitary hormone deficiencies.
The blood supply of the pituitary is unique because it is connected to the hypothalamus. This capillary system is known as the hypothalamohypophyseal portal system. The superior hypophyseal arteries form the primary capillary plexus. This plexus supplies blood to the median eminence. The blood from the median eminence would then drain via the hypophyseal portal veins in a secondary plexus. It is via this system that peptides that are released at the median eminence enter the primary plexus. From that point, the peptides would be transmitted to the adenohypophysis via the hypophyseal portal veins to the secondary plexus. The portal system has fenestrated capillaries that would allow for exchange between the hypothalamus and the pituitary. The cells of the adenohypophysis express G-protein coupled receptors that bind to the peptides allowing the release of hormones from the anterior pituitary.
The majority of the blood supply of the adenohypophysis is derived from the paired superior hypophyseal arteries. These arteries arise from the medial aspect of the internal carotid artery just after leaving the cavernous sinus. The superior hypophyseal emerges 5-mm distal to the origin of the ophthalmic artery and then will go on to form the primary capillary network found in the median eminence. This capillary plexus supplies blood to the pars distalis. The capillary plexus is drained by the anterior and posterior hypophyseal portal veins.
Short veins from the pituitary gland drain into the neighboring dural venous sinuses.
Variations of the pituitary gland sizes are seen in regard to hormonal demands. In younger adults, especially those going through puberty, have larger glands. These glands entirely occupy the space of the pituitary fossa and have a large convex upper border. Those individuals that are older will tend to have an empty-looking pituitary fossa. The most dramatic change can be seen in pregnancy when it is dramatically enlarged and in some cases can be mistaken for an adenoma.
It has also been documented that sexual dimorphism exists. Through magnetic resonance imaging (MRI) it was seen that females ages 14 to 17 years were documented to have a larger pituitary gland. Those females that were 19 years, compared to those that were older (20 years and older) demonstrated this correlation between pituitary volume and age. Males did not show these phenomena.
Surgery of the pituitary gland is considered when medical management has been deemed a failure, intolerable, or in cases of removal of pituitary tumors.
The best technique for pituitary surgery is transsphenoidal surgery. An endonasal incision creates a path to the anterior wall of the sphenoid sinus. Once the sphenoid bone is broached (a fracture is created), the sellar floor can be penetrated with a durotomy to view the sellar region. The area is enhanced visually with an operative microscope. The advantages of going the transsphenoidal route allow there to be minimal surgical trauma, less blood loss, avoidance of generic complications of craniotomy, and direct visualization of the gland. Complications of transsphenoidal surgery include persistent cerebrospinal fluid (CSF) rhinorrhea, panhypopituitarism, transient DI, postoperative meningitis, cranial nerve injury, vascular damage, and stroke due to vasospasm or thromboembolism.
However, recently there been an increase in the use of the transnasal transsphenoidal approach. This approach allows for a decreased time of hospital stay, an increase in patient comfort, and less nasal packing.
Any remnants of Rathke’s pouch can produce mass effect signs and symptoms. Rathke’s cleft cysts can accumulate fluid and start to expand allowing compression of nearby structures. Vestigial remnants of the pouch can also form craniopharyngiomas. These are benign tumors that are slow-growing and are seen in very young or in the very old. These benign tumors are superseller. They are mostly cystic but can be solid and encapsulated. Two forms of craniopharyngiomas are seen. The first is an adamantinomatous form which contains calcifications and projections into the adjacent brain tissue. These projections can cause an intense inflammatory reaction. The second form, the papillary form, lacks the calcification and cysts and much more approachable surgically.
Tumors of the pituitary gland are common. Majorities arise from the adenohypophysis and are usually nonsecretory adenomas that are benign.
Pituitary adenomas can be classified as microadenomas (less than 1 cm) or macroadenomas (greater than 1 cm). It is the macroadenomas that have a mass effect on the adjacent structures. If the pituitary gland itself is compressed, it can cause hypopituitarism. A macroadenoma can also cause the compression of the optic chiasm which would result in bitemporal hemianopsia. Headaches, cranial nerve palsies, and hydrocephalus due to blockage of the outflow of the third ventricle.
The majority of secretory adenomas would secrete a single hormone. It is only a very few (1% to 2%) of these adenomas would secrete two or more hormones. An example of a common dual hormone secretion would be growth hormone and prolactin.
The most common secretory adenoma would be prolactinomas. The bigger the secretory prolactin adenoma, the more hormone production there is. Prolactinomas can present with galactorrhea but may not always be present. The second most common secretory adenoma is growth hormone-secreting adenomas. This would be followed by ACTH secreting adenomas, gonadotrophic adenomas (LH and FSH), and thyrotroph tumors.
Hyperprolactinemia can be related to hypersecretion due to a prolactinoma, or it can be due to a “stalk effect.” The hypothalamus usually secretes dopamine, and it is transported via the pituitary stalk to the adenohypophysis. In the adenohypophysis, the dopamine inhibits the lactotrophs from secreting prolactin. The transport of dopamine can be disrupted in two ways. A large macroadenoma with suprasellar extension would cause this "stalk effect." There would be a disruption in the transport of dopamine. Head trauma would also cause a stalk effect. Lactotroph hyperplasia would develop without dopamine inhibition.
Lymphocytic hypophysitis is an inflammatory disorder that would typically present during or right after pregnancy. It is believed to be caused by an autoimmune process. Sarcoidosis (systemic inflammatory disease) can affect the pituitary as well but has to be differentiated from tuberculosis and syphilis.
Empty Sella Syndrome
It is during radiological imaging that the sella turcica may appear empty due to a flattened or shrunken pituitary gland.
Primary Empty Sella syndrome: There is chronic intracranial hypertension along with a defect in the diaphragm sella. This would allow intradural contents to herniate into the Sella allowing there to be compression of the gland. Endocrine abnormalities would result in causing hypopituitarism and even visual symptoms of mass effect. This condition is most commonly seen in obese women with multiple pregnancies.
Secondary Empty Sella syndrome: A variety of problems can cause this condition. These can range from injury and trauma, treated pituitary tumors, infections, surgery in the pituitary region, or even Sheehan syndrome. This too can cause endocrine abnormalities.
This occurs due to the infarction of the pituitary gland due to hypovolemia caused by obstetric hemorrhage. Usually, clinical manifestation occurs in the form of the absence of milk production. The pituitary function can further decline over time.
This is a life-threatening syndrome that calls for immediate neurosurgical treatment. There would be a sudden onset of visual dysfunction, severe headache, and pituitary insufficiency. This would call for immediate neurosurgical involvement.
One of the common genetic disorders that are encountered in clinical practice is multiple endocrine neoplasia-1 (MEN-1). Neoplastic growth is seen in the pancreas, parathyroid, and pituitary. Other genetic disorders that can see is of the PIT1 gene would cause deficiencies in GH, PRL, and TSH.
Pituitary function failure can result from developmental abnormalities that would lead to a decrease or total failure of pituitary hormone failure.
Holoprosencephaly: During embryonic development, there is an abnormality in the development of the fetal forebrain. The result of this would lead to abnormal hypothalamus with associated facial dysmorphism. Facial abnormalities could include cleft palate, absent nasal septum, and widely spaced eyes.
Septo-optic dysplasia: There is either absence of or hypoplasia of the optic chiasm, optic nerves, and the agenesis or hypoplasia of the septum pellucidum; corpus callosum.
Transcription factor mutations: Any mutations in the transcription factors (for example, PIT1) would lead to developmental abnormalities in the formation and differentiation of the pituitary gland.
Other causes: Other causes can cause the pituitary gland to fail in the secretion of its hormones. Many conditions that can affect the pituitary can be trauma, inflammation (bacterial, viral, or fungal), and radiation to the brain and hypothalamus. The effect of radiation depends on the age at which radiation and the dose of radiation.
|||Larkin S,Ansorge O, Development And Microscopic Anatomy Of The Pituitary Gland null. 2000 [PubMed PMID: 28402619]|
|||Nakayama T,Yoshimura T, Seasonal Rhythms: The Role of Thyrotropin and Thyroid Hormones. Thyroid : official journal of the American Thyroid Association. 2018 Jan [PubMed PMID: 28874095]|
|||Drummond JB,Ribeiro-Oliveira A Jr,Soares BS, Non-Functioning Pituitary Adenomas null. 2000 [PubMed PMID: 30521182]|
|||Jirikowski GF, Diversity of central oxytocinergic projections. Cell and tissue research. 2018 Nov 29 [PubMed PMID: 30498946]|
|||Cao J,Lei T,Chen F,Zhang C,Ma C,Huang H, Primary hypothyroidism in a child leads to pituitary hyperplasia: A case report and literature review. Medicine. 2018 Oct [PubMed PMID: 30334955]|
|||Allen MJ,Sharma S, Physiology, Adrenocorticotropic Hormone (ACTH) 2020 Jan; [PubMed PMID: 29763207]|
|||Al-Chalabi M,Alsalman I, Physiology, Prolactin 2020 Jan; [PubMed PMID: 29939606]|
|||Nedresky D,Singh G, Physiology, Luteinizing Hormone 2020 Jan; [PubMed PMID: 30969514]|
|||Orlowski M,Sarao MS, Physiology, Follicle Stimulating Hormone 2020 Jan; [PubMed PMID: 30571063]|
|||Rawindraraj AD,Basit H,Jialal I, Physiology, Anterior Pituitary 2020 Jan; [PubMed PMID: 29763073]|
|||Pirahanchi Y,Jialal I, Physiology, Thyroid Stimulating Hormone (TSH) 2020 Jan; [PubMed PMID: 29763025]|
|||Zubair A,M Das J, Transsphenoidal Hypophysectomy 2020 Jan; [PubMed PMID: 32310602]|
|||Schury MP,Adigun R, Sheehan Syndrome 2020 Jan; [PubMed PMID: 29083621]|
|||Singh G,Mulji NJ,Jialal I, Multiple Endocrine Neoplasia Type 1 (MEN I, Wermer Syndrome) 2020 Jan; [PubMed PMID: 30725665]|